• TLS, CD40–STING Competition in ESCC

  2026-08-26

  A 2025 study identifies tertiary lymphoid structures as favorable prognostic features in treatment-naïve esophageal squamous cell carcinoma and links them to activated, IRF4-positive B cells. Integrated transcriptomic, single-cell, and in vitro analyses support a mechanism in which CD40 and STING compete for TRAF2, shaping non-canonical NF-κB activity, STING modification, and B-cell activation.

• Disulfiram Workflows for Proteasome and Pyroptosis

  2026-08-26

  Disulfiram is a practical research tool for connecting copper-sensitive proteasome inhibition with apoptotic cancer cell death induction. This workflow shows how to use it in purified-enzyme assays, breast cancer MDA-MB-231 cell line research, and carefully controlled pyroptosis experiments without conflating Disulfiram data with the distinct NU6300 mechanism.

• NU6300 Targets Gasdermin D at Cys-191

  2026-08-25

  Jiang et al. identify NU6300 as a covalent gasdermin D inhibitor that targets cysteine-191 and blocks both cleavage and palmitoylation. The study connects this molecular mechanism to reduced pyroptosis, protection in experimental colitis, and improved survival in endotoxemia, while clarifying pathway-specific effects across inflammasomes.

• 3-Deazaneplanocin (DZNep): Assay Strategy

  2026-08-25

  3-Deazaneplanocin (DZNep) is an epigenetic modulator that connects SAHH inhibition with EZH2-dependent chromatin remodeling. This guide focuses on experimental design, orthogonal validation, and context-aware interpretation across AML, hepatocellular carcinoma, and metabolic disease models.

• In Vitro Drug Response Metrics in Cancer Research

  2026-08-24

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of anti-cancer drug response. This framework supports better endpoint selection, time-course design, and interpretation of cytotoxicity experiments.

• MLN2238 Proteasome β5 Inhibition Workflows

  2026-08-24

  Build cleaner proteasome-target engagement, apoptosis, and proteotoxic-stress assays with MLN2238, a reversible inhibitor that favors the β5 site. Its concentration-dependent subunit profile also supports controlled comparisons in multiple myeloma, lymphoma, and bortezomib-resistant cell models.

• 2,7-Dichlorodihydrofluorescein diacetate: ROS Workflows

  2026-08-23

  Build more informative oxidative-stress experiments with DCFH-DA across imaging, flow cytometry, and plate-based screening. This guide connects intracellular ROS readouts with organellar DNA-damage research while emphasizing controls, assay boundaries, and practical troubleshooting.

• Fluoxetine HCl Workflows for Motivation Research

  2026-08-22

  Fluoxetine HCl supports controlled studies of serotonin transport, 5-HT2C signaling, and reward-related phenotypes from membrane assays to animal behavior. This workflow separates acute serotonergic pharmacology from developmental SSRI effects, helping researchers interpret motivation, neurogenesis, and synaptic plasticity results more rigorously.

• Melatonin, RIPK3, and Atrazine-Induced Kidney Injury

  2026-08-22

  The reference study identifies RIPK3-dependent necroptosis as a central mechanism of atrazine-induced renal injury and shows that melatonin suppresses this pathway across in vivo and in vitro models. Its combination of pathway analysis, RIPK3 knockdown, and computational modeling provides a useful framework for distinguishing antioxidant protection from direct regulation of necroptotic signaling.

• Carfilzomib Sensitizes ESCC to Iodine-125 Radiation

  2026-08-21

  This 2025 Translational Oncology study shows that Carfilzomib, also known as PR-171, intensifies iodine-125 seed radiation responses in esophageal squamous cell carcinoma through coordinated apoptosis, paraptosis, and ferroptosis. The work links proteasome inhibition to aggravated endoplasmic reticulum stress and provides a mechanistic framework for studying radiosensitization rather than treating cell death as a single-pathway event.

• ALDH2 Inhibition in APC-Deficient Colorectal Cancer

  2026-08-20

  Liang et al. identify ALDH2 inhibition as a genotype-selective vulnerability in APC-deficient colorectal cancer, with Disulfiram treatment increasing ROS and activating the ASK1/JNK apoptotic pathway. The study combines computational screening, cell-based phenotyping, mechanistic assays, and xenograft validation to support a synthetic-lethal strategy for APC-mutant tumors.

• 3-Hydroxybutyrate (BHBA) in Neuroprotection

  2026-08-20

  Use 3-hydroxybutyrate (BHBA) as a controlled ketone-body add-back to dissect neuronal energy metabolism, ferroptosis resistance, and chromatin signaling. This workflow separates direct metabolite effects from whole-body ketosis and remote ischemic conditioning, improving mechanistic resolution in stroke and metabolic disease research.

• ALDH2–APC Synthetic Lethality in Colorectal Cancer

  2026-08-19

  The reference study identifies ALDH2 inhibition with disulfiram as a potential synthetic-lethal strategy for APC-deficient colorectal cancer, linking APC loss to ROS accumulation and ASK1/JNK-driven apoptosis. Its paired cell-model and xenograft findings provide a framework for genotype-informed cancer research while also emphasizing the need to separate ALDH2-dependent effects from disulfiram’s broader pharmacology.

• NU6300 Targets GSDMD Cysteine-191 and Pyroptosis

  2026-08-19

  Jiang et al. identify NU6300 as a covalent gasdermin D inhibitor that reacts with cysteine-191, suppressing GSDMD cleavage, palmitoylation, membrane recruitment, and pore formation. The study connects this mechanism with reduced pyroptotic inflammation and protection in experimental colitis and sepsis, while revealing pathway-specific differences between AIM2, NLRC4, and NLRP3 inflammasomes.

• Syringin Workflow for RCC Combination Research

  2026-08-18

  Syringin offers a practical natural-product entry point for RCC phenotypic screening, apoptosis research, and sunitinib-sensitization studies. This workflow connects solvent-controlled dose testing with EGFR/PI3K/Akt pathway validation, helping researchers distinguish genuine combination effects from assay artifacts.

8529 records 1/569 page Next 12345 下5页 Last page